RNA technology Archives

News and Trends 17 Aug 2022

AUM LifeTech secures $400,000 grant for lung cancer immunotherapy program

AUM LifeTech, Inc., a Philadelphia-based preclinical stage biotech company, has received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to advance its preclinical program in lung cancer immunotherapy using a non-viral RNA-targeting gene therapy approach. “This grant will help advance our preclinical immunotherapy […]

August 17, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Aug 2022

siRNA company Eleven Therapeutics seals $22M funding

Eleven Therapeutics has raised a total of $22 million in seed funding. Among the roster of funders is the Bill & Melinda Gates Foundation, which committed $9 million in funding to Eleven, including $5 million towards future equity investment supporting the development of a first-of-its-kind platform that designs small interfering RNAs (siRNAs) with ultra-long durability […]

August 3, 2022 - 3 minutesmins - By Jim Cornall

In Depth 22 Jul 2022

The coming of age story of RNAi technology

The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two decades of scientific effort, multiple devastating clinical trial setbacks, and billions of dollars spent on research and development, RNAi therapies are finally establishing themselves in […]

July 22, 2022 - 7 minutesmins - By Farhan Mitha

News and Trends 20 Jul 2022

ICL and PlantArcBio look to use RNAi to boost crop yields

ICL, a global specialty minerals company, and ag-biotech company PlantArcBio, Ltd., have announced the development of a novel bio-stimulant technology platform to improve crop yields while having a minimal impact on the environment. The platform uses RNAi (RNA interference) technology to maximize a plant’s natural yield increase mechanisms, without any genetic modification, and was the […]

July 20, 2022 - 2 minutesmins - By Jim Cornall

beta-thalassemia blood APS antiphospholipid syndrome

News and Trends 11 Jul 2022

Study results reveal bleeding episodes are significantly reduced by hemophilia drug

People suffering from a severe blood disorder may only have to take a once-monthly drug following successful results from an ongoing study. Global healthcare company, Sanofi, has been conducting a study into fitusiran prophylaxis and results have shown it reduces bleeds by 61 per cent in people with hemophilia A or B, with or without […]

July 11, 2022 - 4 minutesmins - By Liza Laws

News and Trends 21 Jun 2022

Therorna funding to accelerate circRNA-based platform

Therorna Inc., a Chinese biotech company specializing in the development of circular RNA (circRNA) technology-based new vaccines and therapies, including for COVID-19, has completed a $42 million series A financing round. The funding was co-led by MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital. […]

June 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods

Belgian biopharma firm Ziphius Vaccines is set to collaborate with the University of Antwerp to research and develop a lipid library for optimized delivery systems of self-amplifying RNA-based drugs (saRNA) and therapeutics. Messenger RNA (mRNA) vaccines deliver genetic instructions to cells to create proteins that then train the immune system against a pathogen, such as […]

June 9, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

Amaroq Therapeutics ‘hits early milestones’ in cancer treatment

New Zealand biotech company Amaroq Therapeutics said it is progressing towards clinical trials following a promising initial development phase. The company, a start-up spun out of the University of Otago, is focused on developing a new class of therapeutics that target long non-coding RNAs (lncRNA) in cancer. Sarah Diermeier, chief scientific officer and founder of […]

June 9, 2022 - 2 minutesmins - By Jim Cornall

covid 19 vaccine patent waiver intellectual property ip

News and Trends 15 Jun 2021

Patent Waiver on Covid-19 Vaccines Splits Opinions in Biotech Industry

Attempts to increase global Covid-19 vaccine coverage with a temporary patent waiver have been met with hostility from many big pharma and biotech companies, but some smaller players welcome the idea. With the Covid-19 pandemic still rampaging through many countries and new viral variants popping up with alarming regularity, scuffles over who holds intellectual property […]

June 15, 2021 - 5 minutesmins - By Anita Chakraverty

In Depth 1 Mar 2021

How Are European Biotechs Tackling the Cardiovascular Disease Problem?

Cardiovascular diseases may not regularly grab the headlines, but they’re the leading cause of mortality globally, making up over 30% of all deaths worldwide. While there are many established treatments on the market, there’s still a need for more effective treatments – can biotech companies provide the answer? We all know that frequent exercise, a […]

March 1, 2021 - 9 minutesmins - By Farhan Mitha

Best in Biotech 28 Dec 2020

A Year to Remember: The Biggest European Biotech News in 2020

The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […]

December 28, 2020 - 12 minutesmins - By Jonathan Smith

News and Trends 26 Mar 2020

Silence Therapeutics to Work with AstraZeneca in RNAi Deal Worth up to €3.6B

AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and respiratory diseases. RNA interference, or RNAi, is a relatively new field of medicine in which therapeutic small interfering (si)RNA molecules — known as siRNA molecules — can selectively block genes and thus inhibit the production of disease-causing proteins. John Strafford, […]

March 26, 2020 - 3 minutesmins - By Laura Cowen

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

RNA technology

AUM LifeTech secures $400,000 grant for lung cancer immunotherapy program

siRNA company Eleven Therapeutics seals $22M funding

The coming of age story of RNAi technology

ICL and PlantArcBio look to use RNAi to boost crop yields

Study results reveal bleeding episodes are significantly reduced by hemophilia drug

Therorna funding to accelerate circRNA-based platform

Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods

Amaroq Therapeutics ‘hits early milestones’ in cancer treatment

Patent Waiver on Covid-19 Vaccines Splits Opinions in Biotech Industry

How Are European Biotechs Tackling the Cardiovascular Disease Problem?

A Year to Remember: The Biggest European Biotech News in 2020

Silence Therapeutics to Work with AstraZeneca in RNAi Deal Worth up to €3.6B

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!